Police take photos of distracted drivers from top deck of bus
Operation Top Deck sees specially trained Greater Manchester Police (GMP) officers boarding a Bee Network bus and using cameras from an elevated position to detect dangerous driving behaviour on key roads during peak periods.
Once offences are captured on camera, GMP's motorcycle unit pulls over drivers to "educate them on their behaviour," and traffic offence reports, and notices of intended prosecution, can be issued.
Dangerous driving behaviour includes the so-called "fatal four" offences- drink and drug driving; distractions such as using a mobile phone behind the wheel, speeding and not wearing seat belts.
During an "Operation Top Deck" deployment on May 13, a total of 32 offences were captured over a two-hour period, according to a spokesperson.
Seventeen people were caught using their mobile phone while driving, there were "seven reports" of people not wearing seat belts, were "seven instances" of a vehicle crossing a solid white line and there was one report relating to a vehicle's number plate.
Dame Sarah Storey, active travel commissioner for Greater Manchester, who attended the recent Operation Top Deck deployment, said: "I'd strongly urge that drivers think twice and ask themselves if making a call or answering a text message is really worth the risk.
"Doing so shows no consideration for their own safety or the safety of their passengers or other road users - and drivers who use their mobile phones while driving are four times more likely to be involved in a crash.
"Seeing Operation Top Deck first-hand has given me a fascinating insight into how Greater Manchester Police enforce the roads while reinforcing their commitment to Vision Zero, our region's ambition to end all deaths and life-changing injuries caused by road traffic collisions by 2040.
"I would encourage anyone who witnesses unsafe driving, and can safely and legally capture footage, to submit it to GMP through the Operation Snap online portal.
"This will be dealt with by the police, which could lead to further action."
Inspector Bradley Ormesher, from GMP's Roads Policing Unit, said: "We are committed to taking direct and positive action to make roads safer across Greater Manchester, and our latest bus-based operation is just one strand of the wider work we are doing.
"Distractions can cost lives and cause serious injury, and we will never take offences lightly where someone is distracted and not fully in control of their vehicle.
"If you are on your phone, not wearing a seatbelt, or driving without due care and attention, you are ultimately breaking the law, and we will take the most appropriate action required.
"Our new operation targets roads at peak times, to allow for maximum impact in our work, and we have already identified dozens of offences when we have been out.
"Driving offences can receive any punishment, from a huge fine, to losing your licence, to potentially spending time behind bars.
"I would urge drivers to think twice before breaking the law."
Operation Top Deck is inspired by National Highways' Operation Tramline, which sees police officers capture footage of dangerous driving from the cabs of heavy goods vehicles.
Since the launch of Operation Tramline in 2015, 51,500 offences have been reported by 35 police forces across the UK, according to a spokesperson.
Last year, more than 3,200 people in Greater Manchester were caught driving while using their phone or not wearing a seat belt properly over a five-week period, as part of a camera trial by Safer Roads Greater Manchester, according to a spokesperson.
To report a dangerous or irresponsible driver, call 101, or 999 in an emergency.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 hours ago
- Business Wire
Tivic Reports Second Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. 'We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems,' stated Tivic CEO Jennifer Ernst. 'To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit the ClearUP business by the end of this year,' continued Ernst. 'I look forward to advancing the commercialization of these life-saving therapies, supporting our strategy to increase shareholder value through this transformation.' Corporate Highlights from the Second Quarter and Subsequent Weeks, included: Securing positive interest in potential military and defense applications for drug candidate Entolimod™ to treat ARS during briefings with the White House and U.S. Food & Drug Administration (FDA) officials. Extending the worldwide license of Entolimod™ to include the treatment of neutropenia, a condition that reduces the body's ability to combat infections and has a wide range of causes - from genetics to cancer treatments and age. Entering into a GMP manufacturing validation agreement with Scorpius Biomanufacturing, Inc. as part of preparing for the FDA biologics license application process. Completing all study visits in the Optimization Study for its patent-pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Raising $1.4 million from the first and second tranche of a preferred equity purchase agreement that provides for up to $8.4 million in total financing. Entering into a $25 million equity line of credit that generated net proceeds of $547,000. Receiving shareholder approval of key measures in support of Tivic transformation strategy. Expanding biopharmaceutical team with regulatory, clinical and business development staff. Naming Lisa Wolf as CFO following her nine-month tenure as interim CFO. Financial Performance: Revenue (net of returns) for the three and six months ended June 30, 2025 totaled $86,000 and $156,000, respectively, compared with $140,000 and $474,000 for 2024. The decreases are due to lower unit sales of ClearUP™ to treat sinus pain and pressure. The lower sales are attributable to decreases in advertising expenses as the company focused resources on accelerating its TLR5 program for the development of Entolimod™ for ARS. Gross profit in the three and six months ended June 30, 2025 was $54,000 and $104,000, respectively, compared to $30,000 and $197,000 in 2024. Gross margin was 67% in the six months ended June 30, 2025, compared to 42% in 2024. Operating expenses in the three and six months ended June 30, 2025 was $2.0 million and $3.5 million, respectively, compared to $1.3 million and $3.0 million in 2024. The increases were primarily due to the addition of the biopharma programs in February 2025. Net loss of $1.9 million for the three months ended June 30, 2025, compared to $1.3 million in the second quarter of 2024. Net loss of $3.4 million for the first half of 2025, compared to $2.7 million for the first half of 2024. At June 30, 2025, cash and cash equivalents totaled $1.2 million, compared with $2.0 million, at December 31, 2024. Subsequent to quarter's end, the Company raised a total of $0.9 million through utilization of its equity line of credit and the sale of Series B Preferred Stock pursuant to its preferred equity purchase agreement. The company has no debt on its balance sheet. Approximately $7.0 million remains available as a committed investment in Tivic through a preferred equity purchase agreement. The company believes the current and committed funding is sufficient to make meaningful progress toward manufacturing validation for Entolimod. Conference Call and Webcast Information Management will host a webcast/conference call today, Thursday, August 14, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the company's second quarter 2025 financial results and provide a business update. Webcast Link An audio replay of the call will be available for the next 90 days from the investor page on the Tivic Health website at About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law. Tivic Health Systems, Inc. Condensed Statements of Operations (in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 REVENUES $ 86 $ 140 $ 156 $ 474 COST OF SALES 32 110 52 277 GROSS PROFIT 54 30 104 197 OPERATING EXPENSES Research and development 655 302 990 558 Sales and marketing 426 207 605 712 General and administrative 907 787 1,949 1,674 TOTAL OPERATING EXPENSES 1,988 1,296 3,544 2,944 NET OPERATING LOSS (1,934 ) (1,266 ) (3,440 ) (2,747 ) OTHER INCOME, NET 3 0 7 0 NET LOSS $ (1,931 ) $ (1,266 ) $ (3,433 ) $ (2,747 ) NET LOSS PER SHARE - BASIC AND DILUTED $ (2.19 ) $ (5.37 ) $ (4.64 ) $ (17.05 ) WEIGHTED-AVERAGE NUMBER OF SHARES - BASIC AND DILUTED 881,294 235,868 739,618 161,103 Expand
Los Angeles Times
13 hours ago
- Los Angeles Times
How many kids must die before L.A. makes streets safer?
Two weeks ago, fourth-grader Nadir Gavarrete was crossing the intersection at New Hampshire Avenue and 4th Street in Koreatown on an e-scooter alongside his 19-year-old brother, Carlos, when both were struck by an alleged drunk driver turning left through a stop sign. Nadir was pronounced dead at the scene, and Carlos was taken to a hospital in serious condition. Although we often refer to incidents like these as 'accidents,' the truth is they're entirely preventable. We live in a city where a pedestrian is injured every five hours and killed every two days. The status quo places L.A. among cities with the highest per capita pedestrian death rates in the U.S. (2.9 per 100,000), according to Los Angeles Police Department data. Koreatown is one of the densest parts of Los Angeles — at 44,000 people per square mile, it's more crowded than most New York City boroughs. Nearly every major street in Koreatown is on the city's 'high injury network' list — the 6% of streets that cause 70% of the traffic injuries and deaths. In other words, L.A. knows how dangerous Koreatown's streets can be. As a result, 14 years ago, in 2011, L.A. applied for a federal grant to improve safety along several city streets, specifically choosing to focus on the intersection of New Hampshire and 4th for one of its projects. The city won the grant money and kicked off community meetings to discuss installing a roundabout at the intersection, as well as adding enhanced crosswalks and other safety improvements to the immediate area. When I was appointed to the Los Angeles Bicycle Advisory Committee in 2019, eight years after those initial community meetings, we were given a presentation by the Los Angeles Department of Transportation that showed a rendering of a beautiful and significantly safer intersection at New Hampshire and 4th, full of crosswalks and traffic calming, and featuring a roundabout. Six years later, there is still no roundabout. The city has yet to even break ground despite holding years of community meetings. Meanwhile, now a 9-year-old boy is dead and his family is left shattered. There are numerous bureaucratic reasons why a single intersection improvement could take more than 14 years. I'm not interested in them. What city leaders need to understand is that when they fail to act with any sense of urgency — even when they've won funding to do so — the inaction has real-life consequences, this time in the form of a little boy's life. What will it take for Los Angeles to have a sense of urgency in actually making our streets safer? We currently spend more on legal settlements to those hurt and killed on our streets than we do on Vision Zero, the city's half-baked effort to reduce traffic deaths. Since Los Angeles declared itself a Vision Zero City in 2015, with the ultimate aim of having no one killed in car crashes on city streets by 2025, deaths and injuries have only gotten worse. In the last few years we've had at least three children hit and killed while walking to school. And yet the city's leaders — facing a budget crisis, much of it of their own making — perpetually underfund LADOT and street safety in general. If a rash of falling elevators killed someone in L.A. every two days and injured someone every five hours, we'd immediately stop using them as the city stepped in to investigate and solve the problem. Yet we seem to just accept the deadly status quo of traffic fatalities as the cost of doing business while walking L.A.'s streets. We don't have to live this way. There are cities that have actually achieved Vision Zero, such as Hoboken, N.J., which has now tallied eight consecutive years without a traffic-related death thanks to significant updates at curbs, crosswalks and intersections. New York City is also steadily making progress on its Vision Zero goals, leading to a per capita pedestrian death rate nearly one-third that of L.A. Los Angeles remains an outlier and will continue to be one unless we properly and urgently fund our Vision Zero efforts and remove the bureaucratic red tape that slows progress: There's no need for 10 community meetings and buy-in from an entire neighborhood to make smart, lifesaving improvements. Michael Schneider is the founder of Streets for All.
Yahoo
15 hours ago
- Yahoo
Police appeal after cyclist has bike stolen 'under threat of violence'
A bike was stolen 'under the threat of violence' according to police in Stockport who are now investigating. The alleged robbery occurred on Grenville Street in Edgeley, just before 8:35pm on Sunday, July 27. The suspect approached the alleged victim and 'under the threat of violence, has stolen a bronze-coloured Raleigh Motus hybrid bike' Greater Manchester Police's Stockport district said iin appeal on their Facebook page. READ MORE: 'It must have been slipped into my lemonade at my 81st birthday party' READ MORE: Man, 30, saw £1,300 Universal Credit payment hadn't arrived... the reason left him stunned Join our Stockport WhatsApp group HERE Officers have published a picture of the bike as part of an appeal for witnesses Anyone who saw what happened, or who may have information, is asked to call GMP on 101 quoting log number 3009 of July 27. Never miss a story with the MEN's daily Catch Up newsletter - get it in your inbox by signing up here -- Day in day out, our reporters in the Manchester Evening News newsroom bring you remarkable stories from all aspects of Mancunian life. However, with the pace of life these days, the frenetic news agenda and social media algorithms, you might not be getting a chance to read it. That's why every week our Features and Perspectives editor Rob Williams brings you Unmissable, highlighting the best of what we do - bringing it to you directly from us. Make sure you don't miss out, and see what else we have to offer, by clicking here and signing up for MEN Daily News. And be sure to join our politics writer Jo Timan every Sunday for his essential commentary on what matters most to you in Greater Manchester each week in our newsletter Due North. You can also sign up for that here. You can also get all your favourite content from the Manchester Evening News on WhatsApp. Click here to see everything we offer, including everything from breaking news to Coronation Street. If you prefer reading our stories on your phone, consider downloading the Manchester Evening News app here, and our news desk will make sure every time an essential story breaks, you'll be the first to hear about it. And finally, if there is a story you think our journalists should be looking into, we want to hear from you. Email us on newsdesk@ or give us a ring on 0161 211 2920.
